The Pfizer project commenced as the business was Wyeth Pharmaceuticals. The design was targeted for North America. The scope included supply network planning for their finished goods distribution along with demand planning used as a rough cut demand pending final monthly resolution of a business forecast. Following the acquisition by Pfizer, the business processes were tested to see where competitive Pfizer business advantages would be compromised by adapting the incumbent Wyeth design. The scope was widened to global and included DP, SNP and PPDS. Documentation of all major business processes had been designed with ARIS and connected to the SAP Solution Manager. This level of process documentation provided a testing forum that required documented exceptions versus a traditional “nice to have” approach to keep business as usual. As a result most of the incumbent design moved from Wyeth to global Pfizer saving significant dollars, achieving synergy of a merger that can only be dreamed of in other mergers, and executed with a global/regional business analytical dashboard that delivers a business advantage.
